Toll like receptor modulator compounds
The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D]pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
1. A compound which is
or a pharmaceutically acceptable salt thereof.
2. A compound which is
3. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
4. A pharmaceutical composition comprising the compound of claim 2 , and a pharmaceutically acceptable excipient.
5. A compound which is
or a pharmaceutically acceptable salt thereof.
6. A compound which is
7. A pharmaceutical composition comprising the compound of claim 5 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
8. A pharmaceutical composition comprising the compound of claim 6 , and a pharmaceutically acceptable excipient.
9. A compound which is
or a pharmaceutically acceptable salt thereof.
10. A compound which is
11. A pharmaceutical composition comprising the compound of claim 9 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
12. A pharmaceutical composition comprising the compound of claim 10 , and a pharmaceutically acceptable excipient.
13. A compound which is
or a pharmaceutically acceptable salt thereof.
14. A compound which is
15. A pharmaceutical composition comprising the compound of claim 13 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
16. A pharmaceutical composition comprising the compound of claim 14 , and a pharmaceutically acceptable excipient.